UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 17, 2017

 

PARATEK PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

 

 

Delaware

 

001-36066

 

33-0960223

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

75 Park Plaza

Boston, MA

02116

(Address of principal executive offices)

(Zip Code)

(617) 807-6600

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( § 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( § 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

 

Item 7.01  Regulation FD Disclosure.

 

On July 17, 2017, Paratek Pharmaceuticals, Inc., or the Company, issued a press release announcing positive top-line results from a Phase 3 clinical study of its broad-spectrum investigational antibiotic, omadacycline, for the treatment of acute bacterial skin and skin structure infections.  This study represents the third positive Phase 3 registration study of omadacycline, which will be used to support marketing applications to the United States Food and Drug Administration and the European Medicines Agency. A copy of this press release is attached hereto as Exhibit 99.1.

 

The Company plans to host a webcast and conference call related to the top-line data at 4:30 p.m. EDT on July 17, 2017. The presentation and a link to the webcast will be available under “Events and Presentations” in the Investor Relations section of the Company’s website at www.paratekpharma.com.

 

The information in this Current Report on Form 8-K is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information contained herein or the presentation materials or webcast referenced herein.

 

Item 9.01  Financial Statements and Exhibits.

 

 

(d)

Exhibits

 

 

 

 

 

 

 

Exhibit No.

 

Description

 

 

99.1

 

Press Release of Paratek Pharmaceuticals, Inc. dated July 17, 2017.

 

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 17, 2017

 

 

 

PARATEK PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

 

By:

 

/s/ William M. Haskel

 

 

 

 

 

 

Name: William M. Haskel

 

 

 

 

 

 

Title: SVP, General Counsel and Corporate Secretary

 

 

 


 

 

EXHIBIT INDEX

 

 

 

 

 

 

 

Exhibit No.

 

Description

 

 

99.1

 

Press Release of Paratek Pharmaceuticals, Inc. dated July 17, 2017.

 

 

 

Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Paratek Pharmaceuticals Charts.
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Paratek Pharmaceuticals Charts.